Results 131 to 140 of about 44,864,774 (235)

Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg   +1 more
wiley   +1 more source

Good clinical trial funding practices: how can public funders reduce the risk of trial failure and improve health impact? [PDF]

open access: yesTrials
Hulstaert F   +8 more
europepmc   +1 more source

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz   +5 more
wiley   +1 more source

Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing ...
Noor A. Nahid   +302 more
wiley   +1 more source

Preventing Chronic Disease (PCD) [PDF]

open access: yes
IntroductionDisparities in enrollment of adults in cancer clinical trials are well documented, but little is known about the attention given to this topic in comprehensive cancer control (CCC) plans.

core  

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

Home - About - Disclaimer - Privacy